Beyond Weight Loss: GLP-1 Health Benefits on Immune- and Mitochondrial Function
The effects of GLP-1 agonists have been extensively studied in clinical trials, particularly focusing on their immunomodulatory properties and impacts on mitochondrial function. This is crucial for promoting longevity in patients with metabolic disorders.
GLP-1 (glucagon-like peptide-1) is a hormone that is released naturally when food is consumed. Its physiological effects include increasing satiety, the feeling of being full; lowering blood glucose levels by increasing insulin release and reducing glucagon release; and slowing gastric emptying, which also reduces glucose release into the bloodstream. GLP-1 receptor agonists have similar effects to the natural GLP-1 hormone Often developed as diabetes medications (e.g. Ozempic) for their blood glucose lowering effects, GLP-1 agonists became well-known as aids for weight loss (e.g. Wegovy). However, clinical trial results indicate beneficial effects beyond weight loss and blood glucose management, promoting longevity via multiple pathways.
Immunomodulatory Effects
A significant body of evidence indicates that GLP-1 receptor agonists, such as liraglutide, semaglutide and exenatide, not only improve glycemic control but also exhibit beneficial effects on cardiovascular health and renal function, which are critical for longevity in patients with type 2 diabetes mellitus (T2DM) (Monami et al., 2011; Moellmann et al., 2018; Qin & Song, 2019; Wang, 2023). Clinical trials have demonstrated that GLP-1 receptor agonists can modulate immune responses, potentially reducing inflammation and improving outcomes in various metabolic conditions. For instance, studies have shown that these agonists can inhibit microglial activation and promote mitophagy, which is crucial for maintaining mitochondrial health and function (Yang et al., 2022; Yu et al., 2018). This immunomodulatory effect is particularly relevant in the context of diabetes, where chronic inflammation is a contributing factor to disease progression and complications (Fan, 2023). Furthermore, the anti-inflammatory properties of GLP-1 receptor agonists may also play a role in enhancing cognitive function and reducing the risk of neurodegenerative diseases, which are associated with aging and longevity (Hunter & Hölscher, 2012; Hernández et al., 2015).
Enhancing Mitochondrial Function
In addition to their immunomodulatory effects, GLP-1 receptor agonists have been shown to positively influence mitochondrial function. Research indicates that these agents can enhance mitochondrial biogenesis and improve energy metabolism in various cell types, including pancreatic beta cells and cardiomyocytes (Kang et al., 2015; Wang, 2023). For example, exendin-4 has been reported to alleviate mitochondrial dysfunction and oxidative stress in cardiac cells, which is vital for preventing diabetic cardiomyopathy and preserving cardiac function (Yu et al., 2018; DeNicola et al., 2014). Moreover, the activation of pathways such as AMPK signaling by GLP-1 receptor agonists contributes to improved mitochondrial energy status, thereby supporting cellular health and longevity (Wang, 2023). The implications of these findings are significant, as they suggest that GLP-1 receptor agonists may not only manage blood glucose levels effectively but also promote longevity through their multifaceted effects on the immune system and mitochondrial function. By mitigating the detrimental impacts of chronic inflammation and enhancing mitochondrial health, these agents could potentially extend the lifespan and improve the quality of life for individuals with type 2 diabetes (Monami et al., 2011; Yang et al., 2022; Yu et al., 2018; Wang, 2023).
In conclusion, the clinical trials investigating GLP-1 receptor agonists have provided substantial evidence of their immunomodulatory effects and benefits on mitochondrial function, both of which are crucial for promoting longevity in patients with metabolic disorders.
DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., … & Zhao, T. (2014). Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Ajp Endocrinology and Metabolism, 307(8), E630-E643. https://doi.org/10.1152/ajpendo.00109.2014
Fan, Y. (2023). The utilization of glucagon-like peptide 1 agonists and risk of following external eye diseases in type 2 diabetes mellitus individuals: a population-based study. Healthcare, 11(20), 2749. https://doi.org/10.3390/healthcare11202749
Hernández, C., Bogdanov, P., Corraliza, L., Garcia-Ramírez, M., Solà-Adell, C., Arranz, J., … & Simó, R. (2015). Topical administration of glp-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes, 65(1), 172-187. https://doi.org/10.2337/db15-0443
Hunter, K. and Hölscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neuroscience, 13(1). https://doi.org/10.1186/1471-2202-13-33
Kang, M., Oh, T., & Cho, Y. (2015). Glucagon-like peptide-1 increases mitochondrial biogenesis and function in ins-1 rat insulinoma cells. Endocrinology and Metabolism, 30(2), 216. https://doi.org/10.3803/enm.2015.30.2.216
Liu, Q., Anderson, C., Broyde, A., Polizzi, C., Fernandez, R., Baron, A., … & Parkes, D. (2010). Glucagon-like peptide-1 and the exenatide analogue ac3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovascular Diabetology, 9(1). https://doi.org/10.1186/1475-2840-9-76
Moellmann, J., Klinkhammer, B., Onstein, J., Stöhr, R., Jankowski, V., Jankowski, J., … & Lehrke, M. (2018). Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy. Diabetes, 67(11), 2410-2419. https://doi.org/10.2337/db17-1212
Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C., Iacomelli, I., … & Mannucci, E. (2011). Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Experimental Diabetes Research, 2011, 1-10. https://doi.org/10.1155/2011/215764
Nuamnaichati, N., Mangmool, S., Chattipakorn, N., & Parichatikanond, W. (2020). Stimulation of glp-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in h9c2 cardiomyoblasts: potential role of epac/pi3k/akt pathway. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.00805
Qin, J. and Song, L. (2019). Glucagon-like peptide-1 (glp-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. https://doi.org/10.21203/rs.2.16671/v1
Wang, L. (2023). Glp-1 receptor agonist improves mitochondrial energy status and attenuates nephrotoxicity in vivo and in vitro. Metabolites, 13(11), 1121. https://doi.org/10.3390/metabo13111121
Yang, F., Wang, X., Qi, J., Zhang, K., Jiang, Y., Feng, B., … & Ma, X. (2022). Glucagon-like peptide 1 receptor activation inhibits microglial pyroptosis via promoting mitophagy to alleviate depression-like behaviors in diabetic mice. Nutrients, 15(1), 38. https://doi.org/10.3390/nu15010038
Yu, W., Zha, W., & Ren, J. (2018). Exendin‐4 and liraglutide attenuate glucose toxicity‐induced cardiac injury through mtor/ulk1‐dependent autophagy. Oxidative Medicine and Cellular Longevity, 2018(1). https://doi.org/10.1155/2018/5396806
Zobel, E., Ripa, R., Scholten, B., Curovic, V., Kjær, A., Hansen, T., … & Størling, J. (2021). Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Scientific Reports, 11(1). doi.org/10.1038/s41598-021-97967-0